After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future

CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.